Consumer DTC and CPG, healthcare and telehealth, and functional ingredient businesses operate under different constraints, but the underlying commercial failures are often structurally similar.
Pricing gets set without channel math. Acquisition assumptions get built against the wrong buyer population. Compliance architecture arrives after the funnel is already designed. Growth models depend on behaviors the market never actually exhibited.
Breakline identifies those structural failures before they get more expensive.
Different markets produce different failure signatures. The diagnostic logic stays the same. What changes are the constraint surfaces, the assumptions, and the math nobody runs until the budget is already committed.
Most consumer growth failures are not demand failures. They are commercial architecture failures that present as execution problems.
Customer acquisition gets blamed when conversion was never competitive. Pricing reflects founder intuition rather than channel economics. Retention assumptions depend on subscription behavior the offer never actually earns. Distribution expansion gets pursued before the margin structure can survive it.
The pattern is predictable because the assumptions are familiar.
CAC inflation after warm audience exhaustion. The model assumes infinite efficient acquisition. It is usually buying the highest-intent segment first. Once that audience is exhausted, CAC climbs sharply and the economics change faster than the forecast assumes.
Weak conversion misdiagnosed as a traffic problem. The site explains the product but does not convert the buyer. Conversion rates far below category benchmark get blamed on acquisition instead of architecture.
Pricing that works in DTC and collapses in distribution. The model prices from internal cost logic or competitive intuition without fully modeling retailer margin, distributor economics, promotional pressure, and channel dilution.
LTV assumptions unsupported by actual buyer behavior. The refill cadence, subscription incentive, or usage pattern does not produce the retention the model requires. Acquisition appears viable until repeat behavior fails.
Commercial decisions made against an unresolved brand structure. Branded house versus house of brands never gets resolved explicitly, so ICP, pricing, channel strategy, and messaging all drift from an unstable foundation.
Documented finding: A consumer brand producing 18 monthly orders from traffic that should have produced 135 at category benchmark. Four structural problems surfaced before the next major spending decision. See the full finding →
Healthcare growth models fail differently because the commercial system includes operational, clinical, and regulatory dependencies that most acquisition models ignore.
Patient acquisition does not convert on generic consumer funnel math. Provider onboarding carries real adoption cost. Clinical review extends conversion timelines. Pharmacy throughput can cap growth before demand is ever fully tested. In some models, acquisition channels are not merely expensive, but structurally unavailable until certification, claims posture, and compliance architecture are in place.
The constraint is rarely just marketing.
Patient acquisition assumptions built against a buyer pool that does not exist at modeled scale. The qualified patient population at a given price point, indication profile, or acquisition channel is often a fraction of the total market used in forecast assumptions.
Growth constrained by operational throughput before demand is fully tested. Provider capacity, pharmacy fulfillment, clinical staffing, or care coordination becomes the limiting factor long before acquisition efficiency is the real issue.
Commercial architecture built before channel eligibility exists. Claims posture, platform policy, certification requirements, payment processor restrictions, and regulatory structure are commercial constraints when they determine whether acquisition can happen at all.
The cost of provider enablement is missing from the model. Training, workflow integration, prescribing friction, protocol review, EMR coordination, and internal champion development are often excluded from acquisition assumptions despite directly determining adoption velocity.
Conversion math that ignores clinical reality. Patient interest does not equal prescription completion. Intake, scheduling, review, prescribing, fulfillment, and follow-up create timelines the original funnel rarely reflects.
Documented finding: A telehealth growth model built around CAC assumptions that failed basic public-company benchmark validation, while the business had unresolved provider, operational, and compliance issues. See the full finding →
Commercial models in claims-sensitive categories fail when ingredient logic gets mistaken for finished-goods economics.
An ingredient that looks viable at manufacturing cost can become structurally unworkable once distribution margin, retailer economics, trade spend, and consumer pricing realities are layered in. Claims strategy often assumes substantiation that does not exist at the specific formula, dose, or delivery format being sold. In B2B commercialization, adoption math frequently ignores reformulation cost, label revision, regulatory review, and operational switching friction.
The pitch focuses on mechanism of action. The buyer's decision turns on total cost of adoption.
The commercial model fails long before the science does.
Ingredient economics that collapse at finished-goods scale. A viable ingredient cost at manufacturing level becomes structurally unworkable once distributor margin, retailer economics, promotional pressure, and final consumer pricing are fully modeled.
Commercial claims built ahead of defensible substantiation. Mechanism-of-action narratives, performance claims, or conversion messaging often exceed the evidentiary standard required for the exact formulation being commercialized.
B2B adoption assumptions that ignore operational switching cost. Commercial adoption requires reformulation, label updates, regulatory review, operational validation, and internal championing. Those costs are invisible in the pitch and obvious in the rejection.
The wrong competitive frame. The product is positioned against adjacent brands when the real competitor is the incumbent behavior the buyer already defaults to.
Commercial architecture built around the product instead of the buyer. The team understands the ingredient, formulation, or mechanism, but has not clearly defined the buyer, use case, or purchase behavior required for the model to hold.
Documented pattern: Ingredient and supplement models frequently appear economically viable at manufacturer margin while failing once real distribution economics, substantiation constraints, and adoption friction are modeled. See the full finding →
Five questions. One business day. A direct answer. Initial diagnostic review is no-cost.
If there's a real issue worth solving, I'll tell you where it is. If there isn't, I'll tell you that too.